/ Panacea Biotec Introduces Tetravalent Vaccine Against DTP And HIB ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 26 December 2016

Panacea Biotec, one of India's leading research based health Management Company, announce launch of Tetravalent Vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib).

Panacea Biotec is committed to protect children from vaccine-preventable diseases, Easyfour­ TT (DTwP-Hib), world's first fully liquid Tetravalent vaccine launch in India will protect infant from Diptheria, Tetanus, Whopping Cough, Hib-Meningitis.

Commenting on the occasion, Dr. Rajesh Jain, Jt. Managing Director, Pancea Biotec Limited said, Panacea Biotec will remain committed to its mission "Innovation in Support of Life" and continue to provide the latest and most affordable preventive and therapetic care to patients across the globe. Our highly talented and committed scientific team are doing a wonderful job in combining cutting edge scientific know-how and patient understanding to deliver affordable and quality products aimed at improving the overall patient health and well being."

Easyfour-TT is a sterile and uniform suspension, manufactured using CD P technology with WHO Pre-Qualified antigens which ensures good quality, high illimuogenicity and less reactogenicity. Being fully liquid, product requires no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.

or Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717